News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
73–95
Matches
95
Sources here
18
Companies here
1
Search results Stored financial headlines

Active search

95 matching headlines

Ticker or company: AXSMMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Webull Analyst action Main company 🇺🇸 United States

AXSOME THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $265 FROM $250

Leerink Partners has raised its target price for Axsome Therapeutics Inc. (AXSM) to $265 from $250. This change suggests an increased positive outlook from the financial institution regarding the company's future performance. The article is very brief and does not provide further details on …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year-over-year. The stock opened at …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a "hold" to a "strong sell" rating. This comes despite a broader "Moderate Buy" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.26 missing …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi

BMO Capital has initiated coverage on Axsome Therapeutics (AXSM) with an Outperform rating and a price target of $310.00. While GuruFocus indicates the stock is 2.1% undervalued with a GF Value™ of $226.26, its GF Score™ of 52/100 points to average performance, burdened by …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TipRanks Earnings Main company 🇺🇸 United States

Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides

Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
marketscreener.com Analyst action Main company 🇺🇸 United States

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the initiation of …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Axsome Therapeutics (NASDAQ:AXSM) has received a "Moderate Buy" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a larger-than-expected loss of $1.26 per share, …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.5% in the first quarter, though it still holds a significant position. Axsome Therapeutics reported mixed quarterly results, beating revenue expectations but missing on earnings per share. Despite the mixed results and …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MSN Market update Main company 🇺🇸 United States

Axsome gains as narcolepsy therapy undergoes FDA review

Axsome Therapeutics' stock rose after the FDA accepted its New Drug Application for solriamfetol for narcolepsy, setting a PDUFA date for February 12, 2026. The therapy has shown promise in improving wakefulness and reducing excessive daytime sleepiness in narcolepsy patients. This marks a positive …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Analyst action Main company 🇺🇸 United States

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL)

Three analysts have issued bullish sentiments on several healthcare companies. Andrew Tsai from Jefferies maintained a Buy rating on Axsome Therapeutics with a $380.00 price target, while Ami Fadia from Needham maintained a Buy rating on Harmony Biosciences Holdings with a $45.00 price target. …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

Responsive Playbooks and the AXSM Inflection

This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM), highlighting weak near-term sentiment but strong long-term potential. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and details multi-timeframe signal analysis with specific support and resistance levels. The analysis …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
AllSci Analyst action Main company 🇺🇸 United States

Axsome's AXS-12 Advances to FDA Review for Cataplexy

The FDA has accepted Axsome Therapeutics' New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy, setting a PDUFA target action date of May 1, 2027. AXS-12 aims to be a non-scheduled, orally dosed option for daytime use, distinct …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sahm Earnings Main company 🇺🇸 United States

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy

Axsome Therapeutics (AXSM) has received FDA acceptance for its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy patients, with a target decision date set and no advisory committee meeting planned. This regulatory milestone provides increased visibility for investors, potentially expanding …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
grafa.com Analyst action Main company 🇺🇸 United States

Axsome FDA application accepted for 2027 target date

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy. This acceptance sets a formal target action date of May 1, 2027, for the drug, which is designed to address the sudden loss …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Axsome gets FDA filing acceptance for narcolepsy drug AXS-12

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy patients, setting a target action date of May 1, 2027. The drug, which has Orphan Drug Designation, targets the sudden muscle tone loss …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Market update Main company 🇺🇸 United States

Axsome gains FDA review for narcolepsy therapy (AXSM:NASDAQ)

Axsome Therapeutics' shares rose in premarket trading after the U.S. FDA accepted its marketing application for AXS-12 (reboxetine), an experimental therapy for narcolepsy. This marks a significant step for the neurology drug developer in bringing its treatment to market.

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

FDA accepts Axsome Therapeutics (NASDAQ: AXSM) AXS-12 narcolepsy NDA

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027, and does not …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Analyst action Main company 🇺🇸 United States

Axsome Therapeutics Announces FDA Acceptance of NDA for AXS-12 in Narcolepsy Cataplexy; PDUFA Date Set for May 1, 2027

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application (NDA) for AXS-12, a treatment for cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting for …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Analyst action Main company 🇺🇸 United States

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Axsome Therapeutics announced that the FDA has accepted its New Drug Application (NDA) for AXS-12 (reboxetine) for treating cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting for …

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro News Company research Main company 🇺🇸 United States

Axsome’s 60% quarter pauses with a 127% Fair Value premium and lighter volume

AXSM slipped 1.8% for the week but remains only 3.7% below its 52-week high, leaving a constructive trend intact while confirmation has become less forceful.

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Sharemaestro Market Watch Weekly signal Main company 🇺🇸 United States

Axsome Therapeutics Inc (AXSM) finishes week 9.8% higher in active trend

The CNS-therapy developer’s twelve-week return is now 62.6%, putting the move in a broader biotech rebound rather than a single-week move.

AXSM main company
Sharemaestro market context Trend signal active 52 weeks +80.3% AXSM stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context